Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0699790 (colon cancer)
 28,837 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Nineteen patients with metastatic liver tumor (9 of gastric cancer, 5 of colon cancer, 2 of pancreatic cancer, one each of mammary cancer, cholecystic cancer, carcinoid of biliary tract) and one patient with primary liver cancer were treated by endogenously induced LAK therapy consisting of transhepatic arterial infusion with ADM or MMC for induction therapy and OK-432 and rIL-2 (TGP-3) for immunotherapy. The following results were obtained. 1) Clinical response for liver tumor showed no CR but 8 cases of PR, for an overall response rate of 42.1%. 2) Reduced tumor marker value was noted in 76.5% cases, and 50% survival term became 349 days after the therapy. 3) Many CD4 and CD8 positive mononuclear cells had infiltrated around liver tumor after therapy by immuno-histochemical staining of surface marker. 4) NK activity of peripheral blood lymphocytes was markedly reduced soon after the therapy and continued for about 4-7 days, while in cases of combined subcutaneous administration with OK-432, NK activity showed only a slight decrease.
 ...
PMID:[Significance of antitumor effects and immunological response on endogenously induced LAK therapy for primary or metastatic liver tumor]. 153 Feb 92

This study was undertaken to investigate the effects of a single infusion of radiolabelled murine monoclonal antibody (MAb) on peripheral blood leukocytes in cancer patients. Eleven patients with disseminated colon cancer, malignant melanoma, or lung adenocarcinoma were infused with 111In-labelled anti-ZCE 025, anti-p97 type 96.5c, or LA 20207 MAb, respectively. Blood samples were obtained before infusion, immediately after infusion (1 hr), and at 4 and 7 days postinfusion. Flow cytometry analysis of CD3+, CD4+, CD8+, CD16+, and CD19+ lymphocytes showed increasing CD4:CD8 ratios in seven patients after infusion. This phenomenon was not restricted to antibody subclass or to type of cancer. Two of the remaining patients exhibited a marked post-infusion increase in CD8+ cells. In all three patients with malignant melanoma, decreasing levels of CD16+ lymphocytes were noted after infusion and natural killer cell cytotoxicity showed fluctuations which paralleled the changes in the CD16+ subpopulation. Oxygen radical production by phagocytic cells was markedly affected in three subjects. These results suggest that a single infusion of radiolabelled murine MAb may alter the balance of critical lymphocyte subpopulations and modulate other leukocyte responses in cancer patients.
 ...
PMID:Effects of radiolabelled monoclonal antibody infusion on blood leukocytes in cancer patients. 196 68

This study was undertaken to determine whether infusion of a unique ZCE/CHA bifunctional antibody (BFA, 5-40 mg) could alter the composition and functions of peripheral blood leucocytes in 18 patients with colon cancer. The BFA is made by combining chemically the Fab' fragments of two murine monoclonal antibodies. One fragment (ZCE 025) binds to the carcino-embryonic antigen (CEA) and the other (CHA 225) to an epitope, present on an 111In-benzyl EDTA analog of bleomycin (BLEDTA IV) and on 111In-hydroxy-ethyl-thiourea benzyl EDTA (EOTUBE). The radiolabelled epitope (111In-BLEDTA IV or 111In-EOTUBE) was given 4 days after prelocalization with BFA. Peripheral blood samples were tested before BFA infusion, at the end of infusion (1 h later), and at 4 and 7 days post-infusion. A 50% or greater suppression in lymphocyte responsiveness to phytohaemagglutinin (PHA) and concanavalin A (Con A) was seen in 13 out of 18 and 12 out of 18 subjects, respectively, at some time after BFA infusion; this was especially evident in those patients with pre-infusion stimulation indices of greater than 50 (PHA) and/or greater than 10 (Con A). In contrast, natural killer (NK) cell cytotoxicity and oxygen radical production increased in five out of 15 and in seven out of 18 subjects, respectively. Little or no change was observed in CD3, CD4, CD8, CD16, and CD19 markers on lymphocyte subpopulations as determined by flow cytometry. These data suggest that significant changes in mitogen-induced lymphoproliferation. NK cell cytotoxicity, and oxygen radical production can occur in a substantial proportion of cancer patients after infusion of the ZCE/CHA bifunctional antibody system. The immunomodulation was unrelated to initial BFA dose, dose of BFA as a carrier, or to subsequent infusion of either form of the 111In epitope. The clinical significance of these phenomena, if any, remains to be determined.
 ...
PMID:Changes in leucocyte populations following murine bifunctional antibody infusion in colon cancer patients. 202 55

This report describes the identification and biochemical characterization of a new proliferation- and activation-associated membrane Ag. The M21C5 Ag (Mr 80 to 85 kDa) initially was immunoprecipitated from 125I-cell surface-labeled HT29 human tissue culture colon cancer cells by using a monoclonal antibody (M21C5) prepared from HT-29 immunized BALB/c mice. The M21C5 Ag is a glycoprotein as shown by metabolic labeling with 3H-leucine and 2-[3H]-mannose. It has a broad distribution on most proliferating tissue culture cell lines tested, but is absent from several normal human tissues that were examined. Although not detected on unstimulated PBL, the expression of the M21C5 Ag could be induced by stimulation of PBL with the T cell mitogens PHA or Con A. Two-color fluorescence analysis showed that M21C5 is expressed on both CD4 and CD8 activated T cells. After mitogen stimulation, the expression of the M21C5 Ag was delayed relative to the expression of IL-2 and transferrin receptors. M21C5 glycoprotein was shown to be an integral membrane protein that is phosphorylated primarily on serine residues. Based on its biochemical and tissue distribution properties, M21C5 phosphoglycoprotein appears distinct from other known proliferation and activation-associated molecules.
 ...
PMID:An 80 to 85 kilodalton human phosphoglycoprotein associated with cell activation. 318 79

The KM231 mAb recognizing sialyl Lewis(a) (sLe(a)) epitope of glycoprotein or glycolipid expressed on various human cancers was used to prepare bispecific antibody (BSAb) containing anti-CD3 x anti-sLe(a) mAb. The effect of anti-CD3 x anti-sLe(a) BSAb on the induction of cytotoxicity by activated T cells was investigated. The activated CD3+ T cells expressing CD8 or CD4 were induced from human peripheral blood mononuclear cells by culture with recombinant IL-2 plus immobilized anti-CD3 mAb. The activated CD8+ and CD4+ T cells showed marginal cytotoxicity against tumor cells by themselves. However, addition of anti-CD3 x anti-sLe(a) BSAb resulted in a great augmentation of their cytotoxicity against gastrointestinal tumor cells. The BSAb also triggered IL-2 production of CD4+ helper/killer T cells during lysis of tumor cells. Moreover, the BSAb was demonstrated to have a potent in vivo antitumor activity against human colon cancer implanted in nude mice by combination with CD4+ helper/killer cells. These results demonstrated that sLe(a) antigen might be a good target molecule for BSAb-directed adoptive tumor immunotherapy.
 ...
PMID:Tumor-associated glycoantigen, sialyl Lewis(a) as a target for bispecific antibody-directed adoptive tumor immunotherapy. 772 41

The role of lymphocyte surface binding sites for wheat germ agglutinin (WGA) in the negative regulation of cancer patients was investigated. The number of WGA binding sites on the surface of each lymphocyte ranged from 10(7) to 10(8). Fluorescein isothiocyanate (FITC)-conjugated WGA, bound to the majority of peripheral blood lymphocytes (PBL) with two peaks of fluorescent intensity was expressed either dimly or brightly. The increase in lymphocytes brightly expressing WGA fluorescent intensity (WGA bright lymphocytes) significantly correlated with the number of WGA binding sites. The suppression of lymphocyte proliferation mediated by the purified soluble suppressor factor (SSF) significantly correlated with an increase in the WGA bright lymphocyte population (P < 0.05). A significantly greater number of WGA bright lymphocytes in PBL was found in patients with esophageal, gastric, breast, or colon cancer, than in those with benign diseases or in healthy controls. Furthermore, an increase in WGA bright lymphocytes was found in subsets expressing the antigens CD8 dimly or CD16. Thus, it is suggested that the number of WGA binding sites may increase mainly on the surface of effector cells such as NK cells and CD8-positive killer T cells in cancer patients, triggering the negative regulation mediated by SSF.
 ...
PMID:The role of lymphocyte surface binding sites for wheat germ agglutinin in the negative regulation of cancer patients. 821 8

Tumor-specific T lymphocytes (CTL) are proliferated in vitro to induce by a stimulation with butanol-extracted soluble antigen (CBE) and human recombinant interleukin-2 (IL-2) from peripheral lymphocytes of cancer patients. Peripheral blood T lymphocytes (PBL-T), tumor infiltrating lymphocytes (TIL) and lymph node lymphocytes (LNC) from patients with colon cancer were stimulated in vitro with CBE and IL-2. Single stimulation with CBE (1 x 10(-3) micrograms/ml) also activated the proliferative response of the PBL-T (p < 0.01). On the other hand, high-dose (0.25-2 micrograms/ml) significantly inhibited the proliferation of the PBL-T that had been stimulated with 20U/ml IL-2 (p < 0.001). The IL-2 receptor expression of PBL-T, TIL and LNC was also activated with low-dose CBE and IL-2. The surface markers of stimulated lymphocytes responded anti-CD3 and CD8 monoclonal antibodies, but some TIL and LNC displayed CD3 and CD4 phenotype. The lymphocytes responding anti-CD8 monoclonal antibody possessed the cytotoxic activity against autologous tumor cells, but not the lymphocytes responding anti-CD4 monoclonal antibody. The results suggested that low-dose CBE and IL-2 augment the IL-2 receptor expression of T lymphocytes, thereby the proliferation of the antigen specific cytotoxic T cells.
 ...
PMID:[Characterization of autologous-tumor specific cytotoxic T cells induced by means of butanol-extracted soluble antigen from T lymphocytes in colon cancer patients]. 846 10

We examined the possibility of the use of the IL-4 gene in cancer immuno-gene therapy protocols. Colon carcinoma cell (colon 26) clones engineered to express IL-4 were established. Expression of IL-4 significantly reduced tumorigenicity of colon 26 cells. Administration of anti-IL-4 antibody reversed the non-tumorigenic phenotype of the cells. Mice immunized with MMC-treated IL-4 positive cells rejected challenging IL-4 negative colon 26 cells. Strong CTL responses against colon 26 cells were observed in immunized mice. The lytic activity was tumor specific, and was blocked by the antibody against CD8. Histological examination showed that extensive infiltration of eosinophils occurred on day 5 after inoculation, while lymphocytes became the majority of the infiltrating cells on day 8. These results indicate that the expression of IL-4 in colon 26 cells can induce both eosinophil mediated local tumor killing and T-cell mediated systemic immunity in vivo. The dual mode of action of IL-4 may provide a basis for the advantage of IL-4 secrating tumor cells to apply in the cancer immuno-gene therapy.
 ...
PMID:Expression of interleukin-4 in colon 26 cells induces both eosinophil mediated local tumor killing and T-cell mediated systemic immunity in vivo. 881 May 56

Integrins play an important role in various lymphocyte functions. In this study, tumor-infiltrating lymphocytes (TIL) were isolated from colorectal cancer tissues and the expression of beta1 and beta2 integrins on the TIL was quantitatively examined with two-color flow cytometry. In comparison with peripheral blood lymphocytes (PBL), TIL expressed a lower level of common beta1 chain (CD29) in both CD4 and CD8 subpopulations. Among the associated alpha chains, the expressions of alpha1 (CD49a) and alpha2 (CD49b) were slightly higher in TIL than in PBL, whereas alpha4 (CD49d) and alpha6 (CD49f) were markedly downregulated in TIL. Both alphaL (CD11a) and beta2 (CD18) were reduced in CD8(+) TIL but not in CD4(+) TIL. TIL with the CD8(+) cytotoxic phenotype showed significantly decreased binding to purified intracellular adhesion molecules (ICAM)-1, and vascular adhesion cell molecule (VCAM)-1, and HT29 colon cancer cells, compared with the in counterparts in PBL. The peculiar expression pattern and functional down regulation of these integrins may explain why TIL in colorectal cancer cannot eradicate the malignant cells.
 ...
PMID:Functional expression of beta1 and beta2 integrins on tumor infiltrating lymphocytes (TILs) in colorectal cancer. 1043 7

Integrins play an important role in various lymphocyte functions. In this study, we isolated lamina propria lymphocytes (LPL) and tumor-infiltrating lymphocytes (TIL) from normal and malignant tissues in patients with colorectal cancer, and examined the expression of beta1 and beta2 integrins on these lymphocytes quantitatively with two-color flow cytometry. Both LPL and TIL expressed a lower level of common beta1 chain (CD29) in CD4 and CD8 subpopulations than did peripheral blood lymphocytes (PBL). Among the associated alpha chains, the expression levels of alpha1 (CD49a) and alpha2 (CD49b) were slightly higher, whereas those of alpha4 (CD49d) and alpha6 (CD49f) were markedly reduced in LPL and TIL. No significant differences were observed in expressions of any alpha1 integrin chains between these two lymphocytes populations. Similarly, both alphaL (CD11a) and beta2 (CD18) were down-regulated in TIL and LPL with CD8+ cytotoxic phenotype, but not in those with CD4+ phenotype. CD8+ TIL expressed a slightly but significantly higher level of alphaLbeta2 than did CD8+ LPL. CD8+ LPL and CD8+ TIL consistently showed significantly decreased binding to purified ICAM-1, VCAM-1 and HT29 colon cancer cells as compared with CD8+ PBL. Although CD8+ TIL showed a slightly higher level of adhesion to these substrates than did CD8+ LPL, the level was much lower than that in PBL. The expression pattern and functional down-regulation of these integrins may be one of the reasons why TIL cannot eradicate the cancer cells in colorectal cancer.
 ...
PMID:Functional down-regulation of beta1 and beta2 integrins of lamina propria lymphocytes (LPL) and tumor-infiltrating lymphocytes (TIL) in colorectal cancer patients. 1045 90


1 2 3 4 5 6 7 8 9 10 Next >>